Article info

Original research
Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers

Authors

  • Xu Yang Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Ying Hu Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China PubMed articlesGoogle scholar articles
  • Keyan Yang Genecast Biotechnology Co., Ltd, Wuxi, China PubMed articlesGoogle scholar articles
  • Dongxu Wang Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Jianzhen Lin Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Junyu Long Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Fucun Xie Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Jinzhu Mao Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Jin Bian Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Mei Guan Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Jie Pan Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Li Huo Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Ke Hu Center of Radiotherapy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Xiaobo Yang Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Yilei Mao Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Xinting Sang Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  • Jiao Zhang Genecast Biotechnology Co., Ltd, Wuxi, China PubMed articlesGoogle scholar articles
  • Xi Wang Department of Immunology, School of Basic Medical Sciences, Capital Medical University, Beijing, China PubMed articlesGoogle scholar articles
  • Henghui Zhang Beijing Shijitan Hospital, Capital Medical University, Beijing, China; Ninth School of Clinical Medicine, Peking University, Beijing, China; School of Oncology, Capital Medical University, Beijing, ChinaInstitute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China PubMed articlesGoogle scholar articles
  • Haitao Zhao Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China PubMed articlesGoogle scholar articles
  1. Correspondence to Prof. Haitao Zhao; zhaoht{at}pumch.cn; Prof. Henghui Zhang; zhhbao{at}ccmu.edu.cn; Prof. Xi Wang; xiwang{at}ccmu.edu.cn
View Full Text

Citation

Yang X, Hu Y, Yang K, et al
Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers

Publication history

  • Accepted February 22, 2021
  • First published May 10, 2021.
Online issue publication 
February 07, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.